chr17-58694980-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_058216.3(RAD51C):c.195A>G(p.Arg65Arg) variant causes a synonymous change. The variant allele was found at a frequency of 0.000915 in 1,614,146 control chromosomes in the GnomAD database, including 30 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0014 ( 7 hom., cov: 32)
Exomes 𝑓: 0.00086 ( 23 hom. )
Consequence
RAD51C
NM_058216.3 synonymous
NM_058216.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 3.64
Genes affected
RAD51C (HGNC:9820): (RAD51 paralog C) This gene is a member of the RAD51 family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51 and are known to be involved in the homologous recombination and repair of DNA. This protein can interact with other RAD51 paralogs and is reported to be important for Holliday junction resolution. Mutations in this gene are associated with Fanconi anemia-like syndrome. This gene is one of four localized to a region of chromosome 17q23 where amplification occurs frequently in breast tumors. Overexpression of the four genes during amplification has been observed and suggests a possible role in tumor progression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.53).
BP6
Variant 17-58694980-A-G is Benign according to our data. Variant chr17-58694980-A-G is described in ClinVar as [Likely_benign]. Clinvar id is 136157.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-58694980-A-G is described in Lovd as [Benign]. Variant chr17-58694980-A-G is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population eas. gnomad4 allele frequency = 0.00141 (215/152318) while in subpopulation EAS AF= 0.036 (187/5190). AF 95% confidence interval is 0.0318. There are 7 homozygotes in gnomad4. There are 107 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 7 AD,AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD51C | NM_058216.3 | c.195A>G | p.Arg65Arg | synonymous_variant | 2/9 | ENST00000337432.9 | NP_478123.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51C | ENST00000337432.9 | c.195A>G | p.Arg65Arg | synonymous_variant | 2/9 | 1 | NM_058216.3 | ENSP00000336701.4 |
Frequencies
GnomAD3 genomes AF: 0.00143 AC: 217AN: 152200Hom.: 8 Cov.: 32
GnomAD3 genomes
AF:
AC:
217
AN:
152200
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00303 AC: 762AN: 251446Hom.: 20 AF XY: 0.00267 AC XY: 363AN XY: 135904
GnomAD3 exomes
AF:
AC:
762
AN:
251446
Hom.:
AF XY:
AC XY:
363
AN XY:
135904
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000863 AC: 1262AN: 1461828Hom.: 23 Cov.: 31 AF XY: 0.000799 AC XY: 581AN XY: 727218
GnomAD4 exome
AF:
AC:
1262
AN:
1461828
Hom.:
Cov.:
31
AF XY:
AC XY:
581
AN XY:
727218
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00141 AC: 215AN: 152318Hom.: 7 Cov.: 32 AF XY: 0.00144 AC XY: 107AN XY: 74476
GnomAD4 genome
AF:
AC:
215
AN:
152318
Hom.:
Cov.:
32
AF XY:
AC XY:
107
AN XY:
74476
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
27
AN:
3478
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:20
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:6
Benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 16, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 05, 2014 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 07, 2021 | - - |
Likely benign, no assertion criteria provided | curation | Leiden Open Variation Database | Aug 25, 2011 | Curator: Arleen D. Auerbach. Submitter to LOVD: Ian Campbell. - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 27, 2016 | Variant summary: The RAD51C c.195A>G (p.Arg65Arg) variant involves the alteration of a conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a damaging outcome for this variant. 4/5 splice prediction tools predict no significant impact on normal splicing. ESE finder predicts that this variant may affect ESE sites. However, these predictions have yet to be confirmed by functional studies. This variant was found in 354/122132 control chromosomes (13 homozygotes), predominantly observed in the East Asian subpopulation at a frequency of 0.0396715 (343/8646). This frequency is about 635 times the estimated maximal expected allele frequency of a pathogenic RAD51C variant (0.0000625), suggesting this is likely a benign polymorphism found primarily in the populations of East Asian origin. This variant has been reported in HBOC families, without strong evidence for causality. In addition, multiple clinical diagnostic laboratories classified this variant as benign. Taken together, this variant is classified as benign. - |
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 22, 2019 | - - |
Likely benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Breast-ovarian cancer, familial, susceptibility to, 3 Benign:3
Benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Apr 05, 2023 | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. - |
Benign, criteria provided, single submitter | clinical testing | Counsyl | May 25, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
Hereditary cancer-predisposing syndrome Benign:2
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 27, 2014 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Apr 13, 2015 | - - |
Fanconi anemia complementation group O Benign:2
Benign, criteria provided, single submitter | clinical testing | Counsyl | May 25, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Breast and/or ovarian cancer Benign:1
Benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Nov 09, 2021 | - - |
Fanconi anemia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Malignant tumor of breast Benign:1
Benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | RAD51C, EXON 02, c.195A>G, p.Arg65=, Heterozygous, Benign The RAD51C p.Arg65= variant was identified in 4 of 5232 proband chromosomes (frequency: 0.001) from individuals or families with breast and ovarian cancers of Australian and Danish ethnicity and was not identified in 427 control chromosomes from healthy individuals (Jonson 2015, Thompson 2012). The variant was also identified in dbSNP (ID: rs45511291) as “With Likely benign allele”; in the ClinVar and Clinvitae database as benign by Invitae, GeneDx, Ambry Genetics, and Counsyl, and likely benign by Illumina; and in the LOVD 3.0 database 2X with the following statistical data given: 2 of 1053 (freq.=0.002) and 1 of 134 (freq.0.003). The variant was further identified in the 1000 Genomes Project in 41 of 5000 chromosomes (frequency: 0.001); in HAPMAP-EAS in 40 of 1008 chromosomes (frequency: 0.04), HAPMAP-AFR in 1 of 1322 chromosomes (frequency: 0.0001) and the NHLBI GO Exome Sequencing Project in 1 of 8600 European American and in 5 of 4406 African American alleles. The variant was not identified in the Cosmic and MutDB, databases. The variant was identified in control databases in 773 of 277228 chromosomes at a frequency of 0.003 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017). The variant was identified in the following population at a frequency greater than 1%: East Asian in 748 of 18868 chromosomes (freq: 0.04). The p.Arg65= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. REFERENCES: J√âˆnson L, Ahlborn LB, Steffensen AY, Djursby M, Ejlertsen B, Timshel S,Nielsen FC, Gerdes AM, Hansen TV. Identification of six pathogenic RAD51Cmutations via mutational screening of 1228 Danish individuals with increased riskof hereditary breast and/or ovarian cancer. Breast Cancer Res Treat. 2016Jan;155(2):215-22. doi: 10.1007/s10549-015-3674-y. Epub 2016 Jan 6. PubMed PMID: 26740214. Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, kConFab,Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG.Analysis of RAD51C germline mutations in high-risk breast and ovarian cancerfamilies and ovarian cancer patients. Hum Mutat. 2012 Jan;33(1):95-9. doi:10.1002/humu.21625. Epub 2011 Nov 4. PubMed PMID: 21990120. - |
Breast and Ovarian Cancer Susceptibility Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at